

FIG.1A




FIG.1F



FIG.1B




FIG.1C



FIG. 1D1




FIG. 1D2



FIG. 1E1




FIG. 1E2




FIG. 1G1





FIG. 1G2

pHEX^{lac}

CONDITIONED MEDIUM



β -Hex X-CORRECTS



conditioned medium



control plain medium

FIG.2A

FIG.2B

VSV-G PSEUDOTYPED FIV(Hex)





FIG.3

FIV (Hex)




FIG.4

FIV (Hex) 6.2 maxi prep
1kb⁺ uncut Sca I Not I Sal I Xho I 1kb⁺ Total 1mg
(1μg/μl)




FIG.5




FIG.6




FIG.7




FIG.8






FIG.9






FIG.11




FIG. 11A




FIG. 11B




FIG.12

β -Hex^{XAT}




FIG.13





FIG.14

GLVP/CrePr CELL LINE



pCMV-GLVP

G5/TATA-CrePr

pPGK-lox-Luc-lox-AP



Plain media

10⁻⁸M RU486

Alkaline phosphatase
histochemistry

FIG.15

Hex^{XAT}: Excisionally activated β -hexosaminidase gene




FIG.16A




FIG.16B

FIG.16C

Hex^{XAT}: EXCISIONALLY ACTIVATED β -HEXOSAMINIDASE GENE




FIG.17A

Hex^{XAT}: EXCISIONALLY ACTIVATED β -HEXOSAMINIDASE GENE




FIG.17B




FIG.17C




FIG.18

GM₂ ganglioside immunocytochemistry




FIG.19




FIG.20

PERINATAL GENE THERAPY IN $\text{hexB}^{-/-}$ MICE





FIG.21

Perinatal FIV(Hex) in hexB^{-/-}



5 wks old

FIG.22




FIG.23




FIG. 24




FIG. 26





FIG. 27




FIG. 28




FIG. 29




FIG. 30




FIG. 31




FIG. 32